ArticleInternational journal of clinical pharmacy2013
Delayed recovery from ertapenem induced encephalopathy: case-report and a possible mechanism.
Article in International journal of clinical pharmacy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Neurological Adverse Effects Attributable to β-Lactam Antibiotics: A Literature Review.Drug safety · 2017Pooled it
- Ertapenem-Associated Neurotoxicity in a Patient With Chronic Kidney Disease and Hypothyroidism: A Case Report.Cureus · 2026Article
- Delayed diagnosis of ertapenem-induced delirium in an elderly patient with multimorbidity and septic shock: a case report.Journal of medical case reports · 2026Article
- Ertapenem-induced encephalopathy in a patient with liver abscess and acute kidney injury.BMJ case reports · 2024Article
- Article
- Acute kidney injury-associated delirium: a review of clinical and pathophysiological mechanisms.Critical care (London, England) · 2022Review
- Probable ertapenem-induced encephalopathy; case report and suggested alternatives for chronic prostatitis.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2022Article
- Ertapenem-induced encephalopathy.BMJ case reports · 2020Article
- Ertapenem-associated neurotoxicity in the spinal cord injury (SCI) population: A case series.The journal of spinal cord medicine · 2018Article
- Acute Kidney Injury as a Risk Factor for Delirium and Coma during Critical Illness.American journal of respiratory and critical care medicine · 2017Article
- Status Epilepticus and Delirium Associated with Ertapenem in a Very Elderly Patient with Chronic Kidney Disease and Silent Ischaemic Cerebrovascular Disease.Drug safety - case reports · 2015Article
- Ertapenem-Induced Encephalopathy in a Patient With Normal Renal Function.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
caseThe objective of this case report is to report a patient with moderate renal impairment who developed ertapenem-induced encephalopathy with delayed recovery of up to 2 weeks despite receiving and appropriately adjusted dosage of ertapenem. The patient was managed conservatively with full recovery. Carbapenem related neurotoxicity most commonly manifests as seizure with an estimated incidence of 3 %. There are increasing reports of encephalopathy being related to ertapenem and most commonly subsides within days and extended recovery of up to 2 weeks have only been reported in patients with end-stage renal failure.
conclusionsProlonged ertapenem induced encephalopathy can occur in patients with moderate renal impairment. These patients can be managed conservatively and they should make a complete recovery.
Indexed as
Identifiers
23801127What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.